Gyre Therapeutics, Inc.
NASDAQ: GYRE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ping Zhang
- Employees
- 579
- Headquarters
- San Diego, United States
- IPO year
- 2006
- Market cap
- $595.9M
- Website
- https://www.gyretx.com
Loading GYRE…
Loading profile data…Frequently asked questions about GYRE
What does Gyre Therapeutics, Inc. (GYRE) do?
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is al...
Where does GYRE trade?
Gyre Therapeutics, Inc. (GYRE) trades on the NASDAQ Capital Market.
What sector is GYRE in?
Gyre Therapeutics, Inc. (GYRE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Gyre Therapeutics, Inc.?
Ping Zhang is the chief executive officer of Gyre Therapeutics, Inc. (GYRE).
Where is Gyre Therapeutics, Inc. headquartered?
Gyre Therapeutics, Inc. is headquartered in United States.
Does GYRE pay a dividend?
Gyre Therapeutics, Inc. (GYRE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GYRE go public?
Gyre Therapeutics, Inc. (GYRE) completed its initial public offering in 2006.